

Glomerulonephritis Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/G588E8B17579EN.html>

Date: March 2022

Pages: 104

Price: US\$ 3,250.00 (Single User License)

ID: G588E8B17579EN

Abstracts

This report contains market size and forecasts of Glomerulonephritis Treatment in Global, including the following market information:

Global Glomerulonephritis Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Glomerulonephritis Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

ACH-5228 Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Glomerulonephritis Treatment include Achillion Pharmaceuticals Inc, Anthera Pharmaceuticals Inc, Biogen Inc, Bristol-Myers Squibb Company, Cellmid Ltd, ChemoCentryx Inc, Complexa Inc, Dimerix Bioscience Pty Ltd and GlaxoSmithKline Plc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Glomerulonephritis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Glomerulonephritis Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Glomerulonephritis Treatment Market Segment Percentages, by Type, 2021 (%)

ACH-5228

AMY-101

Atacicept

Avacopan

AVX-002

Global Glomerulonephritis Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Glomerulonephritis Treatment Market Segment Percentages, by Application, 2021 (%)

Home Care

Clinic

Hospital

Global Glomerulonephritis Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Glomerulonephritis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Glomerulonephritis Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Glomerulonephritis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Achillion Pharmaceuticals Inc

Anthera Pharmaceuticals Inc

Biogen Inc

Bristol-Myers Squibb Company

Cellmid Ltd

ChemoCentryx Inc

Complexa Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Merck KGaA

Omeros Corp

Pfizer Inc

Pharmalink AB

Ra Pharmaceuticals Inc

Retrophin Inc

Rigel Pharmaceuticals Inc

Takeda

Visterra Inc

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Glomerulonephritis Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Glomerulonephritis Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL GLOMERULONEPHRITIS TREATMENT OVERALL MARKET SIZE

- 2.1 Global Glomerulonephritis Treatment Market Size: 2021 VS 2028
- 2.2 Global Glomerulonephritis Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Glomerulonephritis Treatment Players in Global Market
- 3.2 Top Global Glomerulonephritis Treatment Companies Ranked by Revenue
- 3.3 Global Glomerulonephritis Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Glomerulonephritis Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Glomerulonephritis Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Glomerulonephritis Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Glomerulonephritis Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Glomerulonephritis Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Glomerulonephritis Treatment Market Size Markets, 2021 & 2028

4.1.2 ACH-5228

4.1.3 AMY-101

4.1.4 Atacicept

4.1.5 Avacopan

4.1.6 AVX-002

4.2 By Type - Global Glomerulonephritis Treatment Revenue & Forecasts

4.2.1 By Type - Global Glomerulonephritis Treatment Revenue, 2017-2022

4.2.2 By Type - Global Glomerulonephritis Treatment Revenue, 2023-2028

4.2.3 By Type - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Glomerulonephritis Treatment Market Size, 2021 & 2028

5.1.2 Home Care

5.1.3 Clinic

5.1.4 Hospital

5.2 By Application - Global Glomerulonephritis Treatment Revenue & Forecasts

5.2.1 By Application - Global Glomerulonephritis Treatment Revenue, 2017-2022

5.2.2 By Application - Global Glomerulonephritis Treatment Revenue, 2023-2028

5.2.3 By Application - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Glomerulonephritis Treatment Market Size, 2021 & 2028

6.2 By Region - Global Glomerulonephritis Treatment Revenue & Forecasts

6.2.1 By Region - Global Glomerulonephritis Treatment Revenue, 2017-2022

6.2.2 By Region - Global Glomerulonephritis Treatment Revenue, 2023-2028

6.2.3 By Region - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Glomerulonephritis Treatment Revenue, 2017-2028

6.3.2 US Glomerulonephritis Treatment Market Size, 2017-2028

6.3.3 Canada Glomerulonephritis Treatment Market Size, 2017-2028

6.3.4 Mexico Glomerulonephritis Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Glomerulonephritis Treatment Revenue, 2017-2028

6.4.2 Germany Glomerulonephritis Treatment Market Size, 2017-2028

6.4.3 France Glomerulonephritis Treatment Market Size, 2017-2028

6.4.4 U.K. Glomerulonephritis Treatment Market Size, 2017-2028

6.4.5 Italy Glomerulonephritis Treatment Market Size, 2017-2028

6.4.6 Russia Glomerulonephritis Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Glomerulonephritis Treatment Market Size, 2017-2028

6.4.8 Benelux Glomerulonephritis Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Glomerulonephritis Treatment Revenue, 2017-2028

6.5.2 China Glomerulonephritis Treatment Market Size, 2017-2028

6.5.3 Japan Glomerulonephritis Treatment Market Size, 2017-2028

6.5.4 South Korea Glomerulonephritis Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Glomerulonephritis Treatment Market Size, 2017-2028

6.5.6 India Glomerulonephritis Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Glomerulonephritis Treatment Revenue, 2017-2028

6.6.2 Brazil Glomerulonephritis Treatment Market Size, 2017-2028

6.6.3 Argentina Glomerulonephritis Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Glomerulonephritis Treatment Revenue, 2017-2028

6.7.2 Turkey Glomerulonephritis Treatment Market Size, 2017-2028

6.7.3 Israel Glomerulonephritis Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Glomerulonephritis Treatment Market Size, 2017-2028

6.7.5 UAE Glomerulonephritis Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Achillion Pharmaceuticals Inc

7.1.1 Achillion Pharmaceuticals Inc Corporate Summary

7.1.2 Achillion Pharmaceuticals Inc Business Overview

7.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings

7.1.4 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)

- 7.1.5 Achillion Pharmaceuticals Inc Key News
- 7.2 Anthera Pharmaceuticals Inc
 - 7.2.1 Anthera Pharmaceuticals Inc Corporate Summary
 - 7.2.2 Anthera Pharmaceuticals Inc Business Overview
 - 7.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.2.4 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.2.5 Anthera Pharmaceuticals Inc Key News
- 7.3 Biogen Inc
 - 7.3.1 Biogen Inc Corporate Summary
 - 7.3.2 Biogen Inc Business Overview
 - 7.3.3 Biogen Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.3.4 Biogen Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.3.5 Biogen Inc Key News
- 7.4 Bristol-Myers Squibb Company
 - 7.4.1 Bristol-Myers Squibb Company Corporate Summary
 - 7.4.2 Bristol-Myers Squibb Company Business Overview
 - 7.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Major Product Offerings
 - 7.4.4 Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.4.5 Bristol-Myers Squibb Company Key News
- 7.5 Cellmid Ltd
 - 7.5.1 Cellmid Ltd Corporate Summary
 - 7.5.2 Cellmid Ltd Business Overview
 - 7.5.3 Cellmid Ltd Glomerulonephritis Treatment Major Product Offerings
 - 7.5.4 Cellmid Ltd Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.5.5 Cellmid Ltd Key News
- 7.6 ChemoCentryx Inc
 - 7.6.1 ChemoCentryx Inc Corporate Summary
 - 7.6.2 ChemoCentryx Inc Business Overview
 - 7.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.6.4 ChemoCentryx Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.6.5 ChemoCentryx Inc Key News
- 7.7 Complexa Inc
 - 7.7.1 Complexa Inc Corporate Summary

- 7.7.2 Complexa Inc Business Overview
- 7.7.3 Complexa Inc Glomerulonephritis Treatment Major Product Offerings
- 7.7.4 Complexa Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
- 7.7.5 Complexa Inc Key News
- 7.8 Dimerix Bioscience Pty Ltd
 - 7.8.1 Dimerix Bioscience Pty Ltd Corporate Summary
 - 7.8.2 Dimerix Bioscience Pty Ltd Business Overview
 - 7.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Major Product Offerings
 - 7.8.4 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.8.5 Dimerix Bioscience Pty Ltd Key News
- 7.9 GlaxoSmithKline Plc
 - 7.9.1 GlaxoSmithKline Plc Corporate Summary
 - 7.9.2 GlaxoSmithKline Plc Business Overview
 - 7.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Major Product Offerings
 - 7.9.4 GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.9.5 GlaxoSmithKline Plc Key News
- 7.10 Merck KGaA
 - 7.10.1 Merck KGaA Corporate Summary
 - 7.10.2 Merck KGaA Business Overview
 - 7.10.3 Merck KGaA Glomerulonephritis Treatment Major Product Offerings
 - 7.10.4 Merck KGaA Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.10.5 Merck KGaA Key News
- 7.11 Omeros Corp
 - 7.11.1 Omeros Corp Corporate Summary
 - 7.11.2 Omeros Corp Business Overview
 - 7.11.3 Omeros Corp Glomerulonephritis Treatment Major Product Offerings
 - 7.11.4 Omeros Corp Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.11.5 Omeros Corp Key News
- 7.12 Pfizer Inc
 - 7.12.1 Pfizer Inc Corporate Summary
 - 7.12.2 Pfizer Inc Business Overview
 - 7.12.3 Pfizer Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.12.4 Pfizer Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)

- 7.12.5 Pfizer Inc Key News
- 7.13 Pharmalink AB
 - 7.13.1 Pharmalink AB Corporate Summary
 - 7.13.2 Pharmalink AB Business Overview
 - 7.13.3 Pharmalink AB Glomerulonephritis Treatment Major Product Offerings
 - 7.13.4 Pharmalink AB Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.13.5 Pharmalink AB Key News
- 7.14 Ra Pharmaceuticals Inc
 - 7.14.1 Ra Pharmaceuticals Inc Corporate Summary
 - 7.14.2 Ra Pharmaceuticals Inc Business Overview
 - 7.14.3 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.14.4 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.14.5 Ra Pharmaceuticals Inc Key News
- 7.15 Retrophin Inc
 - 7.15.1 Retrophin Inc Corporate Summary
 - 7.15.2 Retrophin Inc Business Overview
 - 7.15.3 Retrophin Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.15.4 Retrophin Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.15.5 Retrophin Inc Key News
- 7.16 Rigel Pharmaceuticals Inc
 - 7.16.1 Rigel Pharmaceuticals Inc Corporate Summary
 - 7.16.2 Rigel Pharmaceuticals Inc Business Overview
 - 7.16.3 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
 - 7.16.4 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.16.5 Rigel Pharmaceuticals Inc Key News
- 7.17 Takeda
 - 7.17.1 Takeda Corporate Summary
 - 7.17.2 Takeda Business Overview
 - 7.17.3 Takeda Glomerulonephritis Treatment Major Product Offerings
 - 7.17.4 Takeda Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
 - 7.17.5 Takeda Key News
- 7.18 Visterra Inc
 - 7.18.1 Visterra Inc Corporate Summary
 - 7.18.2 Visterra Inc Business Overview

- 7.18.3 Visterra Inc Glomerulonephritis Treatment Major Product Offerings
- 7.18.4 Visterra Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
- 7.18.5 Visterra Inc Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Glomerulonephritis Treatment Market Opportunities & Trends in Global Market

Table 2. Glomerulonephritis Treatment Market Drivers in Global Market

Table 3. Glomerulonephritis Treatment Market Restraints in Global Market

Table 4. Key Players of Glomerulonephritis Treatment in Global Market

Table 5. Top Glomerulonephritis Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Glomerulonephritis Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Glomerulonephritis Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Glomerulonephritis Treatment Product Type

Table 9. List of Global Tier 1 Glomerulonephritis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Glomerulonephritis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Glomerulonephritis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Glomerulonephritis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Glomerulonephritis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Glomerulonephritis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Glomerulonephritis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Glomerulonephritis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Glomerulonephritis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Glomerulonephritis Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Glomerulonephritis Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Glomerulonephritis Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Glomerulonephritis Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Glomerulonephritis Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Glomerulonephritis Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Glomerulonephritis Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Achillion Pharmaceuticals Inc Corporate Summary

Table 31. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product Offerings

Table 32. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Anthera Pharmaceuticals Inc Corporate Summary

Table 34. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product Offerings

Table 35. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Biogen Inc Corporate Summary

Table 37. Biogen Inc Glomerulonephritis Treatment Product Offerings

Table 38. Biogen Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Bristol-Myers Squibb Company Corporate Summary

Table 40. Bristol-Myers Squibb Company Glomerulonephritis Treatment Product Offerings

Table 41. Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Cellmid Ltd Corporate Summary

Table 43. Cellmid Ltd Glomerulonephritis Treatment Product Offerings

Table 44. Cellmid Ltd Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. ChemoCentryx Inc Corporate Summary

Table 46. ChemoCentryx Inc Glomerulonephritis Treatment Product Offerings
Table 47. ChemoCentryx Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 48. Complexa Inc Corporate Summary
Table 49. Complexa Inc Glomerulonephritis Treatment Product Offerings
Table 50. Complexa Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 51. Dimerix Bioscience Pty Ltd Corporate Summary
Table 52. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Product Offerings
Table 53. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 54. GlaxoSmithKline Plc Corporate Summary
Table 55. GlaxoSmithKline Plc Glomerulonephritis Treatment Product Offerings
Table 56. GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 57. Merck KGaA Corporate Summary
Table 58. Merck KGaA Glomerulonephritis Treatment Product Offerings
Table 59. Merck KGaA Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 60. Omeros Corp Corporate Summary
Table 61. Omeros Corp Glomerulonephritis Treatment Product Offerings
Table 62. Omeros Corp Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 63. Pfizer Inc Corporate Summary
Table 64. Pfizer Inc Glomerulonephritis Treatment Product Offerings
Table 65. Pfizer Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 66. Pharmalink AB Corporate Summary
Table 67. Pharmalink AB Glomerulonephritis Treatment Product Offerings
Table 68. Pharmalink AB Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 69. Ra Pharmaceuticals Inc Corporate Summary
Table 70. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product Offerings
Table 71. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 72. Retrophin Inc Corporate Summary
Table 73. Retrophin Inc Glomerulonephritis Treatment Product Offerings
Table 74. Retrophin Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)
Table 75. Rigel Pharmaceuticals Inc Corporate Summary
Table 76. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product Offerings

Table 77. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 78. Takeda Corporate Summary

Table 79. Takeda Glomerulonephritis Treatment Product Offerings

Table 80. Takeda Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

Table 81. Visterra Inc Corporate Summary

Table 82. Visterra Inc Glomerulonephritis Treatment Product Offerings

Table 83. Visterra Inc Glomerulonephritis Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Glomerulonephritis Treatment Segment by Type in 2021

Figure 2. Glomerulonephritis Treatment Segment by Application in 2021

Figure 3. Global Glomerulonephritis Treatment Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Glomerulonephritis Treatment Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Glomerulonephritis Treatment Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Glomerulonephritis Treatment Revenue in 2021

Figure 8. By Type - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 9. By Application - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 10. By Region - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 11. By Country - North America Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 12. US Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 16. Germany Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 17. France Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 24. China Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Glomerulonephritis Treatment Revenue, (US\$, Mn),

2017-2028

Figure 28. India Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Glomerulonephritis Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Glomerulonephritis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Biogen Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Cellmid Ltd Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. ChemoCentryx Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Complexa Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Merck KGaA Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Omeros Corp Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Pfizer Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Pharmalink AB Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue Year Over

Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Retrophin Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Takeda Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Visterra Inc Glomerulonephritis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Glomerulonephritis Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/G588E8B17579EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G588E8B17579EN.html>